Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF for Pneumonia Prevention in Cirrhosis
NCT03123666Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Apr 2017
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of sargramostim in pneumonia, sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Survival at 1 year. Status: unknown.
02
Drugs
sargramostim
03
Conditions
pneumonia
Beyond the preview
Go deeper on NCT03123666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123666.